Tarceva Related Published Studies
Well-designed clinical trials related to Tarceva (Erlotinib)
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell
lung cancer: a lead-in study. [2012]
Afatinib versus placebo for patients with advanced, metastatic non-small-cell
lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines
of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. [2012]
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of
tivantinib plus erlotinib versus placebo plus erlotinib in previously treated
patients with locally advanced or metastatic, nonsquamous, non-small-cell lung
cancer. [2012]
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III
clinical trial of erlotinib in advanced non-small cell lung cancer. [2012]
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. [2011.09.10]
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. [2011.08.20]
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. [2011.08]
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. [2011.07]
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. [2011.06.20]
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). [2011.06]
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. [2011.05.28]
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. [2011.03.10]
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. [2011.03]
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-cell lung cancer. [2011.01]
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer
after previous platinum-containing chemotherapy: a NICE single technology
appraisal. [2011]
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced
non-small-cell lung cancer after failure of standard first-line chemotherapy
(BeTa): a double-blind, placebo-controlled, phase 3 trial. [2011]
Randomized phase II study of bevacizumab in combination with chemotherapy in
previously untreated extensive-stage small-cell lung cancer: results from the
SALUTE trial. [2011]
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. [2010.12.15]
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. [2010.12]
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? [2010.12]
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. [2010.07]
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. [2010.06]
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. [2010.04.30]
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. [2010.03.03]
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). [2010.01.22]
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. [2010.01]
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumors. [2010]
The SATURN trial: the value of maintenance erlotinib in patients with
non-small-cell lung cancer. [2010]
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer. [2009.08]
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. [2009.05.01]
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. [2009.03.10]
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. [2009.03.10]
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. [2009.03]
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. [2009.02.20]
Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. [2009.01.12]
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. [2009.01.10]
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study. [2008.12]
Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer. [2008.11]
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. [2008.06.03]
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. [2008.06]
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. [2008.05.10]
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. [2008.05]
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. [2008.02.20]
Effect of food on the pharmacokinetics of erlotinib, an orally active epidermal growth factor receptor tyrosine-kinase inhibitor, in healthy individuals. [2008.02]
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. [2008.01]
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. [2007.12]
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. [2007.10.20]
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. [2007.10.10]
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. [2007.07.01]
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. [2007.06]
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. [2007.05.20]
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. [2007.05]
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. [2007.04.20]
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. [2006.08.20]
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. [2006.05]
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. [2006.05]
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. [2006.04.24]
Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. [2006.03]
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. [2005.12]
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. [2005.10]
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. [2005.09.15]
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. [2005.09.01]
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. [2005.09.01]
FDA drug approval summary: erlotinib (Tarceva) tablets. [2005.08]
Erlotinib in lung cancer - molecular and clinical predictors of outcome. [2005.07.14]
Erlotinib in previously treated non-small-cell lung cancer. [2005.07.14]
Well-designed clinical trials possibly related to Tarceva (Erlotinib)
Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer. [2011.11.01]
Optimal Pharmacotherapeutic Strategies for Elderly Patients with Advanced Non-Small Cell Lung Cancer. [2011.10.28]
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. [2011.05.20]
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. [2011.05]
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. [2011.03.01]
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. [2011.01]
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. [2010.11.01]
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma. [2010]
Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). [2010]
Predictive biomarkers for EGFR therapy. [2009.01]
New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. [2008.07.10]
Second-line treatment of advanced non-small cell lung cancer. [2008.04]
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? [2008.04]
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC. [2006.02]
Second-line chemotherapy for non-small cell lung cancer. [2003.08]
Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. [2003.05.15]
Other research related to Tarceva (Erlotinib)
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human
epidermal growth factor receptor inhibitor, versus erlotinib in patients with
advanced non-small-cell lung cancer. [2012]
Role of erlotinib in the treatment of non-small cell lung cancer: clinical
outcomes in wild-type epidermal growth factor receptor patients. [2012]
Clinical outcomes with erlotinib in patients with epidermal growth factor
receptor mutation. [2012]
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with
metastatic HER2-negative breast cancer: clinical and biological activity. [2012]
Efficacy and safety of maintenance erlotinib in Asian patients with advanced
non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN
study. [2012]
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at
progression, versus the reverse sequence, in vulnerable elderly patients with
advanced non small-cell lung cancer selected with a comprehensive geriatric
assessment (the GFPC 0505 study). [2012]
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of
patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a
randomised multicentre, open-label, phase 3 study. [2012]
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract
cancer: a multicentre, open-label, randomised, phase 3 study. [2012]
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced,
non-small cell lung cancer patients aged 70 years or older. [2012]
Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non-Small-Cell Lung Cancer. [2011.12.01]
Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal. [2011.12.01]
Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using 18F-FDG and 3'-Deoxy-3'-18F-Fluorothymidine PET. [2011.12]
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo. [2011.11.23]
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. [2011.11.01]
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials. [2011.11]
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. [2011.10.21]
A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non-Small-Cell Lung Cancer. [2011.10.13]
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). [2011.10.11]
A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor. [2011]
|
